Valo Health, Novo Nordisk Collaborate To Discover And Develop Cardiometabolic Disease Treatments Using Human Data And Artificial Intelligence; Valo Will Receive An Upfront And A Potential Near-term Milestone Payment Of $60M
Portfolio Pulse from Benzinga Newsdesk
Valo Health and Novo Nordisk have partnered to discover and develop treatments for cardiometabolic diseases using human data and artificial intelligence. Valo will receive an upfront and a potential near-term milestone payment of $60M. Valo is also eligible to receive milestone payments for up to 11 programs, totalling up to $2.7 billion, plus R&D funding and potential royalty payments.
September 25, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's partnership with Valo Health could lead to the development of new treatments for cardiometabolic diseases, potentially boosting the company's product portfolio and future revenues.
The partnership with Valo Health could lead to the development of new treatments for cardiometabolic diseases, which would expand Novo Nordisk's product portfolio. The potential milestone payments and royalties could also provide a significant boost to the company's future revenues.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100